文献速递甲状腺疾病

Graves病中甲状腺刺激免疫球蛋白与促甲状腺素受体抗体的意义

Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究对957例新诊断Graves病患者进行回顾性数据分析及随访,发现TSI与TRAb强相关(r=0.873,P<.001),抗体下降缓慢与甲亢未缓解相关;206例停药后随访超12个月者复发率41.26%,TSI阳性者复发更频繁(54.84% vs 35.42%,P<.05),停药时TSI阳性、既往GD史、年龄及轻度甲状腺相关眼病为独立复发预测因素。作者认为TSI和TRAb均阴性时可考虑停用抗甲状腺药物。

要点

  • TSI与TRAb在Graves病中强相关(r=0.873,P<.001)。
  • 治疗1月后甲亢未缓解者抗体下降轻微。
  • 停药时TSI阳性者复发率54.84% vs 35.42%(P<.05)。

核心结论

  • TSI与TRAb在Graves病中强相关,抗体下降缓慢与甲亢未缓解相关。
  • 作者认为TSI和TRAb均阴性时可考虑停用抗甲状腺药物。

研究设计与样本

  • 回顾性数据分析及随访研究,纳入957例新诊断Graves病患者(762例女性,195例男性)。
  • 根据治疗1个月后甲状腺功能分为未缓解组(A组)和缓解组(B组)。
  • 随访研究纳入206例停用抗甲状腺药物后随访超过12个月的患者。

主要发现

  • TRAb与TSI强相关(r=0.873,P<.001)。
  • A组抗体下降为100%(IQR 87.91%-115.1%),B组为100%(IQR 85.03%-118.3%),A组较B组下降幅度更小。
  • 206例随访患者中复发率为41.26%。
  • TSI阳性者复发更频繁(54.84% vs 35.42%,P<.05)。
  • 停药时TSI阳性、既往GD史、年龄及轻度甲状腺相关眼病为独立复发预测因素。

关键数值与推荐

  • TSI与TRAb相关性r=0.873,P<.001。
  • A组抗体下降100%(IQR 87.91%-115.1%),B组100%(IQR 85.03%-118.3%)。
  • 复发率41.26%(206例随访患者)。
  • TSI阳性者复发率54.84% vs TSI阴性者35.42%,P<.05。

临床怎么用

  • 作者认为当TSI和TRAb均阴性时可考虑停用抗甲状腺药物。
  • 停药时TSI阳性、既往GD史、年龄及轻度甲状腺相关眼病为独立复发预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Thyroid-stimulating immunoglobulin (TSI) and thyrotropin receptor antibody (TRAb) are specific biomarkers for Graves disease (GD), but their clinical characteristics are not fully understood. OBJECTIVE: To clarify the clinical features and prognostic significance of TSI and TRAb in patients with GD. METHODS: We conducted a retrospective data analysis and a follow-up study. Medical records of patients newly diagnosed with GD were examined. TSI and TRAb correlations were assessed using Passing-Bablok regression and Bland-Altman plot. Patients were categorized into unresolved (Group A) and resolved (Group B) hyperthyroidism based on thyroid function after 1 month of therapy. The relationship between thyroid function and changes in TRAb and TSI was analyzed. Logistic regression identified relapse risk factors, including TSI levels at antithyroid drugs (ATDs) withdrawal in the follow-up study. RESULTS: Data from 957 patients (762 female and 195 male) revealed a strong correlation between TRAb and TSI (r = 0.873, P < .001). Compared to group B, group A showed minimal antibody decline (100% [interquartile range (IQR) 87.91%-115.1%] and 100% [IQR 85.03%-118.3%], respectively). Among 206 patients followed for over 12 months after ATD discontinuation, the relapse rate was 41.26%. Relapse was more frequent in patients with positive TSI (54.84% vs 35.42%, P < .05). Positive TSI levels at withdrawal, past history of GD, age, and mild thyroid-associated ophthalmopathy were independent relapse predictors. CONCLUSION: TSI and TRAb are strongly correlated in GD, with slow antibody decline linked to unresolved hyperthyroidism. Discontinuing ATDs may be considered when both TSI and TRAb are negative.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Peng R, Xie P, Jin Z, et al. Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease. J Clin Endocrinol Metab. 2025. PMID: 39715350. doi:10.1210/clinem/dgae892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。